Literature DB >> 15998431

Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes.

Yong Lin1, Wei-Fen Xie, Yue-Xiang Chen, Xin Zhang, Xin Zeng, Hui Qiang, Wei-Zhong Chen, Xiu-Jiang Yang, Ze-Guang Han, Zhong-Bing Zhang.   

Abstract

PURPOSE: To investigate the effect of combinational delivery of urokinase-type plasminogen activator (uPA) and hepatocyte growth factor (HGF) genes on hepatic fibrosis.
METHODS: Replication-deficient adenoviral vectors expressing either human HGF (AdHGF) or uPA (AduPA) were generated. HGF gene was transferred into primary cultured hepatocytes and uPA gene to hepatic stellate cell (HSC) to investigate the effect on the biological character of cells. Combinational adenoviruses were infused into hepatic fibrosis rats. Serum markers as well as histological and immunohistochemical examination were carried out to test the reversal of hepatic fibrosis.
RESULTS: Transfection of exogenous HGF gene induced expression of c-met/HGF receptor and stimulated hepatocyte proliferation. uPA gene delivered into HSC decreased the amount of collagen types I and III accompanied with the increased expression of matrix metalloproteinase-2. In vivo, the area of extracellular matrix in the fibrotic liver decreased to 72% in AdHGF-treated rats (P<0.01), 64% in the AduPA-treated group (P<0.01), and 51% in bi-genes transfection (P<0.01), compared with that of the controls. Moreover, immunohistochemical staining of collagen types I and III revealed that combinational genes delivery exerted more effect on reversal of hepatic fibrosis than mono-gene transfection.
CONCLUSIONS: Our study indicated that simultaneous delivery of two antifibrotic genes could confer synergistic effect on hepatic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15998431     DOI: 10.1111/j.1478-3231.2005.01098.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  11 in total

1.  Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis.

Authors:  Satish K Madala; John T Pesce; Thirumalai R Ramalingam; Mark S Wilson; Samantha Minnicozzi; Allen W Cheever; Robert W Thompson; Margaret M Mentink-Kane; Thomas A Wynn
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

2.  Effects of 18α-glycyrrhizin on TGF-β1/Smad signaling pathway in rats with carbon tetrachloride-induced liver fibrosis.

Authors:  Ying Qu; Lei Zong; Mingyi Xu; Yuwei Dong; Lungen Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 3.  New gene therapy strategies for hepatic fibrosis.

Authors:  Adriana M Salazar-Montes; Luis D Hernández-Ortega; Martha S Lucano-Landeros; Juan Armendariz-Borunda
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

4.  Macrophage-specific expression of urokinase-type plasminogen activator promotes skeletal muscle regeneration.

Authors:  Margaret L Novak; Scott C Bryer; Ming Cheng; Mai-Huong Nguyen; Kevin L Conley; Andrew K Cunningham; Bing Xue; Thomas H Sisson; Jae-Sung You; Troy A Hornberger; Timothy J Koh
Journal:  J Immunol       Date:  2011-06-27       Impact factor: 5.422

5.  Adeno-associated virus vector-mediated production of hepatocyte growth factor attenuates liver fibrosis in mice.

Authors:  Kazuhiro Suzumura; Tadamichi Hirano; Gakuhei Son; Yuji Iimuro; Hiroaki Mizukami; Keiya Ozawa; Jiro Fujimoto
Journal:  Hepatol Int       Date:  2007-12-22       Impact factor: 6.047

Review 6.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

7.  Combinatorial gene therapy renders increased survival in cirrhotic rats.

Authors:  Francisco J Gálvez-Gastélum; Aida A Segura-Flores; María D Senties-Gomez; Jose F Muñoz-Valle; Juan S Armendáriz-Borunda
Journal:  J Biomed Sci       Date:  2010-05-28       Impact factor: 8.410

8.  Involvement of hepatic stimulator substance in experimentally induced fibrosis and cirrhosis in the rat.

Authors:  Georgios Gribilas; Apostolos Zarros; Athina Zira; Costas Giaginis; Gerasimos Tsourouflis; Charis Liapi; Chara Spiliopoulou; Stamatios E Theocharis
Journal:  Dig Dis Sci       Date:  2008-12-10       Impact factor: 3.199

Review 9.  Urokinase and its receptors in chronic kidney disease.

Authors:  Guoqiang Zhang; Allison A Eddy
Journal:  Front Biosci       Date:  2008-05-01

10.  Inhibition of Notch signaling by a γ-secretase inhibitor attenuates hepatic fibrosis in rats.

Authors:  Yixiong Chen; Shaoping Zheng; Dan Qi; Shaojiang Zheng; Junli Guo; Shuling Zhang; Zhihong Weng
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.